BioWorld

Aug. 28, 2008

Direct Reprogramming Is New Cell Source for Regeneration

NexMed Shares Fall Hard as Novartis Nixes NDA

Other News To Note

Clinic Roundup

Cell Genesys Falls 70% as Patient Deaths Derail GVAX Phase III

In yet another setback for cancer vaccines, Cell Genesys Inc. terminated one of its two Phase III trials with prostate cancer vaccine GVAX. (BioWorld Today) Read More

Amylin Sinks on Further Byetta Worries: More Deaths Reported

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 11, 2025.

Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

BioWorld

With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...

AI-generated illustration of heart and metabolic impact

Deep Apple signs big Novo deal for cardiometabolic small molecules

BioWorld

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...

Corestemchemon preps US BLA filing for stem cell ALS therapy

BioWorld Asia

Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...